Investiture of next generation probiotics on amelioration of diseases – Strains do matter

Abstract

The roles of newly identified, non-conventional, native gut microbiota bacteria for promotion of health and even therapeutic purposes have rapidly attracted much more attention in contrast to the traditional probiotics. Detailed physiological and molecular evidences on isolation, identification and functional characterization of these various bacteria are rapidly gathering. These potentially beneficial bacteria are gradually grouped to form the next generation probiotics (NGP). Many bacterial species and strains belonging to Actinobacteria, Bacteroidetes, Firmicutes and Verrucomicrobia are gradually highlighted. Notably, NGP may have the potential of being treated as drugs (live biotherapeutic products, LBP); therefore, the requirements for grouping of NGP are much more stringent than traditional probiotics. Comprehensive understandings of effectiveness on amelioration of diseases, safety, physiological, genomic, and metabolomics characteristics, the drug susceptibility pattern and transfer of drug resistance genes, and potential virulence factors are mandatory. Besides, how NPG interact with the host to maintain intestinal integrity and host homeostasis has to be addressed. While most NGP products are currently not commercially available yet, this present review emphasizes the requirements of grouping newly identified microbiota bacteria as NGP. Furthermore, selection of specific functional bacteria to the strain level is essential. We also provide an overview of the potential NGP candidates that could be applied for targeted therapy on specific inflammation related diseases.